Cobalis Corporation
COBALIS COMPANY NEWS 2006

The following are recent important news releases by and about Cobalis, and its premier allergy prevention product PreHistin™:

Note: You will need Adobe Acrobat Reader installed to view the document. Click here to download Adobe Acrobat Reader.

Date   Description Downloads
12/21/06   Cobalis Enters Into $3.85 Million Financing Commitment With an Initial $2.5 Million Closing On Or Before December 26th   e Acrobat pdf file
11/07/06   Cobalis Reports All Patient Diaries in Phase III Clinical Trials for OTC Anti-Allergy Product Candidate are Completed   e Acrobat pdf file
11/02/06   Cobalis Corp. to Present At Rodman & Renshaw 8th Annual Healthcare Conference on November 7   audio file Acrobat pdf file
10/12/06   Cobalis Completes Patient Dosing In Phase III Clinical Trials for OTC Anti-Allergy Product Candidate   e Acrobat pdf file
09/06/06   Cobalis Completes Enrollment in Twin Phase III Clinical Trials For PreHistin™   e Acrobat pdf file
07/25/06   Cobalis Initiates Twin Phase III Clinical Trials For PreHistin™   e Acrobat pdf file
07/19/06   Cobalis Chairman Agrees to Convert Related-Party Debt Into Equity at a Premium to Current Share Price   e Acrobat pdf file
06/21/06   Cobalis&srquo; EU Patent for PreHistin® Becomes Effective   e Acrobat pdf file
06/14/06   Cobalis Provides Update on Clinical Program for PreHistin®   e Acrobat pdf file
05/11/06   Dr. Gerald J. Yakatan Appointed CEO of Cobalis Corp   e Acrobat pdf file
04/05/06   Cobalis Settles Outstanding Litigation with Gryphon Master Fund, L.P.   e Acrobat pdf file
03/14/06   Cobalis PreHistin TM Featured in a Cover-Story of Men's Journal   e Acrobat pdf file
03/01/06   Cobalis presentation at the Wall Street Analyst Forum conference in NY   audio file Acrobat pdf file
02/02/06   Dr. Gerald Yakatan, Former President and CEO of Avanir Pharmaceuticals, Joins Cobalis Board of Director   e Acrobat pdf file
01/19/06   Cobalis PreHistin™ Approval Process To Be Conducted By OTC Division Of FDA   e Acrobat pdf file
 

IMPORTANT NOTICE:
The FDA has not completed evaluation of PreHistin™, and the information and statements contained in this web site are intended for informational purposes only. They are not meant to imply a cure or approved treatment for any disease or condition. You are encouraged to consult your physician for any healthcare questions or concerns you may have about your allergies.